We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
RVP Stock Gains Post Q2 Earnings Despite Fall in Sales & Unit Volumes
Read MoreHide Full Article
Shares of Retractable Technologies, Inc. (RVP - Free Report) have gained 6.1% since the company reported its earnings for the quarter ended June 30, 2026, outperforming the S&P 500 Index’s 1.1% decline over the same period. Over the past month, the stock has risen 5.9% compared with the S&P 500’s 2.4% rise.
Retractable’s Earnings Snapshot
Retractable reported second-quarter 2026 net sales of $7.2 million, down 31.1% from $10.4 million a year earlier. Net income applicable to common shareholders was $2.8 million against a loss of $145,082 in the prior-year quarter, while earnings per share were $0.09 against a loss per share of $0.00.
RVP operates in a single reportable segment comprising safety medical syringes and other safety medical devices. By product, syringe sales increased 5.4% to $6.3 million, while blood collection product sales declined 2.3% to $295,940. EasyPoint needle sales plunged 84.6% to $646,418, and other product sales fell 59.7% to $7,713.
RVP’s Other Key Business Metrics
Domestic revenues declined 30.8% year over year, while domestic unit sales fell 35.1%. Domestic sales represented 81.6% of quarterly revenues compared with 81.3% a year ago. International revenues decreased 32.2%, mainly because of lower EasyPoint needle sales. Overall unit sales declined 36.4%.
Cost of manufactured product fell 34.7% and royalty expense decreased 20.8%. Despite the sharp revenue contraction, gross profit improved to $190,852 from a gross loss of $107,090. The operating loss, however, remained essentially unchanged at $5.1 million.
RVP sourced 53.5% of its second-quarter products from Chinese manufacturers, down from 62% a year earlier.
For the first six months of 2026, cash used in operating activities narrowed to $3.1 million from $5.2 million a year earlier. As of June 30, cash and cash equivalents stood at $2.6 million, while investments in debt and equity securities totaled $37.2 million. Inventories declined to $15.9 million from $17.2 million as of Dec. 31, 2025.
Retractable Technologies, Inc. Price, Consensus and EPS Surprise
Management Commentary and Factors Influencing Retractable’s Results
Management attributed the weaker quarterly sales and unit volumes primarily to the timing of EasyPoint product orders. The year-over-year comparison was also affected by unusually high flu-season product purchases in the second quarter of 2025. Purchasing in 2026 has followed a more traditional pattern, under which most flu-season sales occur in the third quarter.
Quarterly net income benefited materially from a $6.4 million realized gain on the sale of equity securities. By comparison, the year-ago quarter included $1.9 million of litigation proceeds and a $1.6 million unrealized investment gain.
Second-quarter 2026 tariff expense was approximately $46,000, with RVP attributing lower tariff costs versus prior periods to strategic sourcing and increased domestic production.
Tariff exposure remains significant. As of Aug. 1, 2026, most syringe and needle products imported from China faced a 112.5% tariff rate. Retractable is seeking to mitigate the impact through strategic ordering and greater domestic manufacturing.
RVP’s Outlook
Retractable expects international sales of VanishPoint syringes and EasyPoint needles to increase in the second half of 2026 following certification under the European Union Medical Device Regulation. The company also expects commercial quantities of domestically produced 0.5-milliliter syringes to become available as market demand requires during the second half. However, management cautioned that tariffs could continue to materially affect sourcing, operating results and financial position, while near-term manufacturing costs are expected to remain high as domestic production expands.
Retractable’s Other Developments
In April 2026, Retractable reduced its workforce by approximately 16%. The restructuring is expected to generate about $2.2 million in annual wage and benefit savings, equivalent to 13% of estimated workforce costs, partly offset by approximately $122,000 of one-time separation payments. About 58% of the targeted payroll reduction involved manufacturing or manufacturing-support positions, with the remainder affecting sales and sales-support roles.
View the Zacks #1 Rank List
Image: Bigstock
RVP Stock Gains Post Q2 Earnings Despite Fall in Sales & Unit Volumes
Shares of Retractable Technologies, Inc. (RVP - Free Report) have gained 6.1% since the company reported its earnings for the quarter ended June 30, 2026, outperforming the S&P 500 Index’s 1.1% decline over the same period. Over the past month, the stock has risen 5.9% compared with the S&P 500’s 2.4% rise.
Retractable’s Earnings Snapshot
Retractable reported second-quarter 2026 net sales of $7.2 million, down 31.1% from $10.4 million a year earlier. Net income applicable to common shareholders was $2.8 million against a loss of $145,082 in the prior-year quarter, while earnings per share were $0.09 against a loss per share of $0.00.
RVP operates in a single reportable segment comprising safety medical syringes and other safety medical devices. By product, syringe sales increased 5.4% to $6.3 million, while blood collection product sales declined 2.3% to $295,940. EasyPoint needle sales plunged 84.6% to $646,418, and other product sales fell 59.7% to $7,713.
RVP’s Other Key Business Metrics
Domestic revenues declined 30.8% year over year, while domestic unit sales fell 35.1%. Domestic sales represented 81.6% of quarterly revenues compared with 81.3% a year ago. International revenues decreased 32.2%, mainly because of lower EasyPoint needle sales. Overall unit sales declined 36.4%.
Cost of manufactured product fell 34.7% and royalty expense decreased 20.8%. Despite the sharp revenue contraction, gross profit improved to $190,852 from a gross loss of $107,090. The operating loss, however, remained essentially unchanged at $5.1 million.
RVP sourced 53.5% of its second-quarter products from Chinese manufacturers, down from 62% a year earlier.
For the first six months of 2026, cash used in operating activities narrowed to $3.1 million from $5.2 million a year earlier. As of June 30, cash and cash equivalents stood at $2.6 million, while investments in debt and equity securities totaled $37.2 million. Inventories declined to $15.9 million from $17.2 million as of Dec. 31, 2025.
Retractable Technologies, Inc. Price, Consensus and EPS Surprise
Retractable Technologies, Inc. price-consensus-eps-surprise-chart | Retractable Technologies, Inc. Quote
Management Commentary and Factors Influencing Retractable’s Results
Management attributed the weaker quarterly sales and unit volumes primarily to the timing of EasyPoint product orders. The year-over-year comparison was also affected by unusually high flu-season product purchases in the second quarter of 2025. Purchasing in 2026 has followed a more traditional pattern, under which most flu-season sales occur in the third quarter.
Quarterly net income benefited materially from a $6.4 million realized gain on the sale of equity securities. By comparison, the year-ago quarter included $1.9 million of litigation proceeds and a $1.6 million unrealized investment gain.
Second-quarter 2026 tariff expense was approximately $46,000, with RVP attributing lower tariff costs versus prior periods to strategic sourcing and increased domestic production.
Tariff exposure remains significant. As of Aug. 1, 2026, most syringe and needle products imported from China faced a 112.5% tariff rate. Retractable is seeking to mitigate the impact through strategic ordering and greater domestic manufacturing.
RVP’s Outlook
Retractable expects international sales of VanishPoint syringes and EasyPoint needles to increase in the second half of 2026 following certification under the European Union Medical Device Regulation. The company also expects commercial quantities of domestically produced 0.5-milliliter syringes to become available as market demand requires during the second half. However, management cautioned that tariffs could continue to materially affect sourcing, operating results and financial position, while near-term manufacturing costs are expected to remain high as domestic production expands.
Retractable’s Other Developments
In April 2026, Retractable reduced its workforce by approximately 16%. The restructuring is expected to generate about $2.2 million in annual wage and benefit savings, equivalent to 13% of estimated workforce costs, partly offset by approximately $122,000 of one-time separation payments. About 58% of the targeted payroll reduction involved manufacturing or manufacturing-support positions, with the remainder affecting sales and sales-support roles.